Overweight (BMI > 25)NCT07658261
Combined Training (Strength and Endurance) and the Serum Levels of Myostatin and Hormone-sensitive Lipase in Overweight and Obese Men
A study testing Upper Body Combined Training and Lower Body Combined Training in people with Overweight (BMI > 25) and Obesity (BMI>30), run by Arya Habibi at 1 site in Iran.
Trial summary
This randomized controlled trial investigated the effects of upper body-based and lower body-based combined training on serum levels of myostatin (MSTN) and hormone-sensitive lipase (HSL) in overweight and obese men. Read more about this study
- Who is it for?
- Ages 20 to 45 years, men onlyHealthy volunteers can take part
- Conditions the study is for
- Overweight (BMI > 25), Obesity (BMI>30)
- What is being tested?
- Upper Body Combined Training and Lower Body Combined Training
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 36 participants
- Where
- 1 siteIran
- Study dates
- 1 May 2024to 15 Dec 2024
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 20 to 45 years
- Men only
- Healthy volunteers accepted
- Adult
Who may be able to join
- Male participants aged 20 to 45 years.
- Body mass index (BMI) ≥25 kg/m².
- Overweight or obese status.
- No participation in regular resistance or aerobic exercise during the previous 6 months.
- Willingness to participate and provide written informed consent.
Who cannot join
- Presence of metabolic diseases, including diabetes mellitus.
- Presence of cardiovascular or respiratory diseases.
- Musculoskeletal or joint injuries that could interfere with exercise participation.
- Use of anti-obesity medications.
- Use of anabolic steroids, sports supplements, or fat-burning supplements.
- Regular alcohol consumption or tobacco use.
- Absence from more than two training sessions during the intervention period.
- Withdrawal of consent or unwillingness to continue participation.
Trial locations and contacts
1 site in 1 country.
Iran1 site
Faculty of Sports and Health Sciences of the University of Tehran
Tehran, Tehran Province
About this study
Official title: Effect of Upper Body and Lower Body Combined Training (Strength and Endurance) on the Serum Levels of Myostatin and Hormone-sensitive Lipase in Overweight and Obese Men
This randomized controlled trial investigated the effects of upper body-based and lower body-based combined training on serum levels of myostatin (MSTN) and hormone-sensitive lipase (HSL) in overweight and obese men. Myostatin is a myokine involved in the regulation of skeletal muscle growth and adipose tissue metabolism, while HSL is a key enzyme involved in lipolysis and fat mobilization.
Thirty-six overweight and obese men were assigned to either an upper body combined training group, a lower body combined training group, or a non-exercising control group. The intervention consisted of 10 weeks of combined resistance and aerobic training performed three times per week. Serum levels of MSTN and HSL were measured before and after the intervention to determine whether upper body-focused and lower body-focused combined training produce different effects on markers associated with muscle growth and lipid metabolism.
- Conditions
- Overweight (BMI > 25), Obesity (BMI>30)
- Being tested
- Upper Body Combined Training, Lower Body Combined Training
- Medical subject headings
- Overweight, Obesity
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Upper Body Combined TrainingBehavioural
Also called Upper Body Resistance and Aerobic Training
Participants completed a 10-week upper body-focused combined training program performed three times per week. Each session included six upper body resistance exercises (chest press, rowing machine, biceps curl, triceps extension, shoulder press, and abdominal machine exercises) followed by aerobic exercise on a hand ergometer. Resistance training was performed for 3 sets during the first 5 weeks and 4 sets during weeks 6-10, with 8-12 repetitions per set. Aerobic exercise began at 20 minutes and increased by 1 minute each week, reaching 29 minutes in the final week. Exercise intensity was maintained at approximately 57-66% of maximum heart rate during aerobic training.
Lower Body Combined TrainingBehavioural
Also called Lower Body Resistance and Aerobic Training
Participants completed a 10-week lower body-focused combined training program performed three times per week. Each session included six lower body resistance exercises (leg press, leg extension, leg flexion, leg abduction, leg adduction, and calf raise exercises) followed by aerobic exercise on a leg ergometer. Resistance training was performed for 3 sets during the first 5 weeks and 4 sets during weeks 6-10, with 8-12 repetitions per set. Aerobic exercise began at 20 minutes and increased by 1 minute each week, reaching 29 minutes in the final week. Exercise intensity was maintained at approximately 57-66% of maximum heart rate during aerobic training.
| Study group | Role | What they receive |
|---|---|---|
| Upper Body Combined Training | Experimental | Participants completed a 10-week upper body-focused combined training program three times per week. Each session consisted of upper body resistance exercises followed by aerobic exercise performed on a hand ergometer. Resistance training included chest press, rowing machine, biceps curl, triceps extension, shoulder press, and abdominal exercises. Receives: Behavioral: Upper Body Combined Training |
| Lower Body Combined Training | Experimental | Participants completed a 10-week lower body-focused combined training program three times per week. Each session consisted of lower body resistance exercises followed by aerobic exercise performed on a leg ergometer. Resistance training included leg press, leg extension, leg flexion, leg abduction, leg adduction, and calf raise exercises. Receives: Behavioral: Lower Body Combined Training |
| Control | No intervention | Participants in the control group did not participate in the exercise intervention and were instructed to maintain their usual daily activities throughout the 10-week study period. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in serum myostatin (MSTN) concentration
Serum myostatin concentration measured by enzyme-linked immunosorbent assay (ELISA). The outcome was assessed before the intervention and 48 hours after completion of the 10-week training program.
Measured: Baseline and 10 weeks
Change in serum hormone-sensitive lipase (HSL) concentration
Serum hormone-sensitive lipase concentration measured by enzyme-linked immunosorbent assay (ELISA). The outcome was assessed before the intervention and 48 hours after completion of the 10-week training program.
Measured: Baseline and 10 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted18 Jun 2026
- Study start1 May 2024
- Primary completion1 May 2024
- Study completion15 Dec 2024
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Overweight (BMI > 25)Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Participants were randomly assigned to one of three parallel groups: an upper body combined training group, a lower body combined training group, or a non-exercising control group. Each intervention group completed a 10-week training program consisting of resistance and aerobic exercise performed three times per week, while the control group maintained their usual lifestyle habits.
- Masking
- None (open label)
- Enrolment
- 36 participants (actual)
Sponsor and investigators
- Lead sponsor
- Arya Habibi
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor-investigator, Arya Habibi, University of Tehran
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07658261
- Sponsor's protocol ID
- IR.UT.SPORT.REC.1403.064
- Status last verified
- Jun 2026
- First submitted
- 14 Jun 2026
- Last updated
- 23 Jun 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: Individual participant data (IPD) will not be made publicly available. The study was not originally designed with a formal data-sharing plan, and participant-level data contain information that could potentially compromise participant confidentiality.
Study at a glance
From the registry record, last updated by the sponsor on 23 Jun 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effect of Upper Body and Lower Body Combined Training (Strength and Endurance) on the Serum Levels of Myostatin and Hormone-sensitive Lipase in Overweight and Obese Men
- ClinicalTrials.gov ID
- NCT07658261
- Acronym / sponsor ID
- IR.UT.SPORT.REC.1403.064
- Conditions
- Overweight (BMI > 25), Obesity (BMI>30)
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 36 participants (actual)
- Lead sponsor
- Arya HabibiUniversity, hospital or other
- Study start
- 1 May 2024 (actual)
- Primary completion
- 1 May 2024 (actual)
- Study completion
- 15 Dec 2024 (actual)
- First posted
- 18 Jun 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This randomized controlled trial investigated the effects of upper body-based and lower body-based combined training on serum levels of myostatin (MSTN) and hormone-sensitive lipase (HSL) in overweight and obese men. Myostatin is a myokine involved in the regulation of skeletal muscle growth and adipose tissue metabolism, while HSL is a key enzyme involved in lipolysis and fat mobilization.
Thirty-six overweight and obese men were assigned to either an upper body combined training group, a lower body combined training group, or a non-exercising control group. The intervention consisted of 10 weeks of combined resistance and aerobic training performed three times per week. Serum levels of MSTN and HSL were measured before and after the intervention to determine whether upper body-focused and lower body-focused combined training produce different effects on markers associated with muscle growth and lipid metabolism.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 3
- Model description
- Participants were randomly assigned to one of three parallel groups: an upper body combined training group, a lower body combined training group, or a non-exercising control group. Each intervention group completed a 10-week training program consisting of resistance and aerobic exercise performed three times per week, while the control group maintained their usual lifestyle habits.
| Arm | Type | Receives |
|---|---|---|
| Upper Body Combined Training | Experimental | Behavioral: Upper Body Combined TrainingParticipants completed a 10-week upper body-focused combined training program three times per week. Each session consisted of upper body resistance exercises followed by aerobic exercise performed on a hand ergometer. Resistance training included chest press, rowing machine, biceps curl, triceps extension, shoulder press, and abdominal exercises. |
| Lower Body Combined Training | Experimental | Behavioral: Lower Body Combined TrainingParticipants completed a 10-week lower body-focused combined training program three times per week. Each session consisted of lower body resistance exercises followed by aerobic exercise performed on a leg ergometer. Resistance training included leg press, leg extension, leg flexion, leg abduction, leg adduction, and calf raise exercises. |
| Control | No intervention | –Participants in the control group did not participate in the exercise intervention and were instructed to maintain their usual daily activities throughout the 10-week study period. |
Who may qualify
- Ages
- 20 to 45 years
- Sex
- Male only
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (5 listed)
- Male participants aged 20 to 45 years.
- Body mass index (BMI) ≥25 kg/m².
- Overweight or obese status.
- No participation in regular resistance or aerobic exercise during the previous 6 months.
- Willingness to participate and provide written informed consent.
Key exclusion criteria (8 listed)
- Presence of metabolic diseases, including diabetes mellitus.
- Presence of cardiovascular or respiratory diseases.
- Musculoskeletal or joint injuries that could interfere with exercise participation.
- Use of anti-obesity medications.
- Use of anabolic steroids, sports supplements, or fat-burning supplements.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Upper Body Combined TrainingAlso: Upper Body Resistance and Aerobic TrainingParticipants completed a 10-week upper body-focused combined training program performed three times per week. Each session included six upper body resistance exercises (chest press, rowing machine, biceps curl, triceps extension, shoulder press, and abdominal machine exercises) followed by aerobic exercise on a hand ergometer. Resistance training was performed for 3 sets during the first 5 weeks and 4 sets during weeks 6-10, with 8-12 repetitions per set. Aerobic exercise began at 20 minutes and increased by 1 minute each week, reaching 29 minutes in the final week. Exercise intensity was maintained at approximately 57-66% of maximum heart rate during aerobic training. | Behavioural | Upper Body Combined Training |
| Lower Body Combined TrainingAlso: Lower Body Resistance and Aerobic TrainingParticipants completed a 10-week lower body-focused combined training program performed three times per week. Each session included six lower body resistance exercises (leg press, leg extension, leg flexion, leg abduction, leg adduction, and calf raise exercises) followed by aerobic exercise on a leg ergometer. Resistance training was performed for 3 sets during the first 5 weeks and 4 sets during weeks 6-10, with 8-12 repetitions per set. Aerobic exercise began at 20 minutes and increased by 1 minute each week, reaching 29 minutes in the final week. Exercise intensity was maintained at approximately 57-66% of maximum heart rate during aerobic training. | Behavioural | Lower Body Combined Training |
Primary outcome
Change in serum myostatin (MSTN) concentration
Time frame: Baseline and 10 weeks
Serum myostatin concentration measured by enzyme-linked immunosorbent assay (ELISA). The outcome was assessed before the intervention and 48 hours after completion of the 10-week training program.
Change in serum hormone-sensitive lipase (HSL) concentration
Time frame: Baseline and 10 weeks
Serum hormone-sensitive lipase concentration measured by enzyme-linked immunosorbent assay (ELISA). The outcome was assessed before the intervention and 48 hours after completion of the 10-week training program.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 23 Jun 2026.
- Individual participant dataSharing planned: No. Individual participant data (IPD) will not be made publicly available. The study was not originally designed with a formal data-sharing plan, and participant-level data contain information that could potentially compromise participant confidentiality.
Related trials for Overweight (BMI > 25)
RecruitingObservational study
An Open Label Pilot Study Assessing the Impact of Chromium Picolinate Supplementation on Appetite and Cravings in Overweight Individuals
Overweight (BMI > 25), Appetite
Active, not recruiting
Weight Loss and Endocrine Disrupting Chemicals (EDCs): Lifestyle Interventions to Lose Weight and Reduce EDC Exposure in Individuals With Overweight/Obesity
Obesity &Amp;Amp;Amp; Overweight, Environmental Exposure
Not yet recruiting
WB-EMS Combined With Nutritional Guidance for a High-Protein Diet on Body Composition, Muscle Function, Psychological and Functional Outcomes in Older Adults With Excess Adiposity
Overweight (BMI > 25), Obesity & Overweight
Enrolling by invitation
AIM-WEIGHT: AI-Guided Microbiome-Targeted Nutritional Intervention for Weight Loss
Overweight (Without Type 2 Diabetes) With Weight-related Comorbidities, Overweight (BMI > 25)
Recruiting
Probiotic Impact on Cognitive Performance, and Metabolic Outcomes in Overweight Young Adults With Impaired Glucose Regulation
Impaired Glucose Regulation, Impaired Glucose Tolerance (Prediabetes)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Upper Body Combined Training and Lower Body Combined Training in people with Overweight (BMI > 25) and Obesity (BMI>30), run by Arya Habibi at 1 site in Iran.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 23 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Iran. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in serum myostatin (MSTN) concentration (time frame: Baseline and 10 weeks). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 23 Jun 2026.